Heparin coating extends the durability of oxygenators used for cardiopulmonary support.
Acomparative study was performed between a noncoated and heparin-coated cardiopulmonary support (CPS) systems with the same design and structure (Terumo Corporation, Capiox-SX series) to evaluate whether or not heparin coating extends oxygenator service life. Fifty patients underwent CPS from January 1993 until December 1997, and 54 oxygenators (Capiox-SX series) were used. There were 35 noncoated oxygenators (Group NC) and 19 heparin-coated ones (Group HC). Significant predictors for the durability of oxygenators were evaluated by a nonparametric survival analysis and a proportional hazards regression analysis. Thirteen of 35 Capiox-SX and only 2 of 19 Capiox SX-HP revealed gas transfer failure and had to be exchanged. The average life span of the Capiox-SX and Capiox-SX-HP were calculated to be 78.6 +/- 16.8 and 168 +/- 15.4 h, respectively. Group HP showed significantly longer durability than Group NC (p = 0.0017), although there were differences of perfusion index and platelet counts between the 2 groups. Heparin coating of the CPS system remained one of the 2 significant predictors (hazards ratio 8. 871, p = 0.0449) to determine the durability of oxygenators by increasing stepwise multivariate proportional hazards regression analysis, along with anemia with less than 8 g/dl hemoglobin (hazards ratio 9.438, p = 0.0173). Heparin coating of the CPS system assures improved durability because heparin-coated oxygenators have a longer service life than noncoated ones.
Usui
A
A
Department of Thoracic Surgery, Nagoya University School of Medicine, Japan.
Hiroura
M
M
Kawamura
M
M
D000740:Anemia / Q000097:blood; D020099:Coated Materials, Biocompatible / Q000008:administration & dosage / Q000627:therapeutic use*; D004867:Equipment Design; D004868:Equipment Failure; D005069:Evaluation Studies as Topic; D005112:Extracorporeal Circulation / Q000295:instrumentation* / Q000379:methods; D005260:Female; D005544:Forecasting; D006454:Hemoglobins / Q000032:analysis; D006493:Heparin / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D010107:Oxygenators, Membrane; D010477:Perfusion; D010976:Platelet Count; D016016:Proportional Hazards Models; D013499:Surface Properties; D016019:Survival Analysis; D013997:Time Factors
D020099:Coated Materials, Biocompatible; D006454:Hemoglobins; D006493:Heparin